SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Voltaire — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientVoltaire
Date of birth1694-11-21
IdentifiersMRN HR-EN002-SYN-TD; SSN (made up) 000-02-5174
Document date1778-05-06
AuthorHonorine Delacroix-Mensah, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review during weekly radiotherapy. [S]

History of Present Illness

Voltaire returns two weeks after starting the pain plan. He had the first radiotherapy fraction a week ago and the second this morning. Since the first fraction he has passed urine more often, about every two hours by day and twice at night, with mild burning, but the stream is steady and there have been no clots; the urine is pale pink on some days. He takes acetaminophen three times a day and has used eight half tablets of oxycodone in fourteen days, mostly in the evening, with good relief and no drowsiness, confusion, or falls; seven tablets remain in the locked box, and he has taken nothing else for pain or sleep. His bowels open daily on polyethylene glycol and senna. The palliative care team visited him at home last week. The physical therapist from the wellness visit has not yet come. He has lost 0.5 kg and drinks the supplement once a day. He wrote every morning this week. [S]

ElementDetail
RadiotherapyFractions 1 and 2 of 6 given; mild frequency and burning
VoidingSteady stream; nocturia twice; residual 120 mL
Pain2 of 10 on acetaminophen and about one half tablet of oxycodone a day
Opioid safetyEight half tablets used in fourteen days; no sedation, falls, or other sedatives
Weight53.0 kg, down 0.5 kg

Review of Systems

SystemResultFinding
ConstitutionalPositiveMore tired on treatment days; weight down 0.5 kg
GenitourinaryPositiveFrequency every two hours, nocturia twice, mild burning; pale pink urine on some days; no clots
GastrointestinalNegativeBowels open daily; no diarrhea or rectal bleeding
NeurologicalNegativeNo drowsiness, confusion, or falls
PsychiatricNegativeMood steady; sleeping about five hours

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Diphenhydramine 25 mg oral capsule, one capsule at night for sleep (over the counter)One capsule at bedtimeOral route1777-09-01 to 1778-04-06stoppedS
Tamsulosin 0.4 mg oral capsule, one capsule at bedtimeOne capsule 30 minutes after the evening mealOral route1778-04-06activeS
Polyethylene glycol 3350, 17 g in a glass of water once daily17 g dissolved in water once dailyOral route1776-01-15activeS
Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 7 daysOne tablet twice daily with food for 7 daysOral route1778-04-20 to 1778-04-26completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth three times daily (3 g a day)Two tablets three times daily; no more than 3 g a dayOral route1778-04-22activeS
Oxycodone 5 mg oral tablet, one half tablet (2.5 mg) by mouth every 6 hours if needed for bladder pain not relieved by acetaminophen, no more than three doses a day; 15 tablets dispensedHalf a tablet every 6 hours as needed; no more than three half tablets a dayOral route1778-04-22activeS
Sennosides 8.6 mg oral tablet, two tablets at bedtime while taking oxycodoneTwo tablets at bedtimeOral route1778-04-22activeS
Naloxone 4 mg nasal spray, one spray in one nostril for suspected opioid overdose; call 911; may repeat in 2 to 3 minutes in the other nostrilOne spray for suspected overdose; repeat after 2 to 3 minutes if no responseNasal route1778-04-22activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1778-05-06Body height170cmS
1778-05-06Body weight53kgS
1778-05-06Body mass index (BMI) [Ratio]18.3kg/m2S
1778-05-06Systolic blood pressure122mm[Hg]S
1778-05-06Diastolic blood pressure68mm[Hg]S
1778-05-06Heart rate80/minS
1778-05-06Respiratory rate16/minS
1778-05-06Body temperature36.7CelS
1778-05-06Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1778-05-06Hemoglobin [Mass/volume] in Blood10.8g/dL13.2-16.6 g/dLLowS
1778-05-06Leukocytes [#/volume] in Blood by Automated count6.910*3/uL3.4-9.6 10*3/uLNormalS
1778-05-06Platelets [#/volume] in Blood by Automated count23110*3/uL150-400 10*3/uLNormalS
1778-05-06Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
1778-05-06Creatinine [Mass/volume] in Serum or Plasma1.2mg/dL0.74-1.35 mg/dLNormalS
1778-05-06Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1773)/1.73 sq M60mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1778-05-06US Urinary bladder Volume post void120mLBelow 100 mL; 300 mL or more suggests chronic retentionHighS
1778-05-06International Prostate Symptom Score [IPSS]15{score}S
1778-05-06Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S

Physical Exam

Vital signs recorded on 1778-05-06; see the Vital Signs section. [S]

SystemFinding
GeneralThin, alert, and lively; not drowsy; pupils normal size
CardiovascularBlood pressure 122/68 mmHg; heart rate 80, regular
RespiratoryRespiratory rate 16; oxygen saturation 96 percent
AbdomenSoft; mild suprapubic tenderness; bladder not palpable
SkinNo skin reaction over the pelvis

Problems

ProblemClinical statusVerificationCodeProvenance
Visible blood in the urine for three weeks with clots, and a weak stream, straining, and frequent small voids, in a man of 83; under evaluationresolvedconfirmed R31.0S — Synthetic presenting problem echoing his documented urinary complaints and last illness; superseded by the diagnosis at the third chronic-care visit.
Chronic urinary retention with overflow (post-void residual 460 mL at intake), worsened by a nightly anticholinergic sleep aid; drained by an indwelling catheteractiveconfirmed R33.8S — Synthetic finding echoing the strangury and catheterization documented in his last weeks.
Acute kidney injury from bladder outlet obstruction (creatinine 1.68 mg/dL, from 1.1 mg/dL a year earlier)resolvedconfirmed N17.9S — Synthetic finding; it echoes, without asserting, the later encyclopedia term uremia.
Benign prostatic hyperplasia with lower urinary tract symptoms: prostate about 78 mL on CT, enlarged, firm, and smooth on examination, PSA 6.4 ng/mL with a PSA density of 0.08; no prostate biopsy, by shared decisionactiveconfirmed N40.1S — Synthetic diagnosis echoing the very large prostate described at the 1778 autopsy; whether that prostate was malignant is unknown (CLM-0012).
Squamous cell carcinoma of the bladder, keratinizing, posterior wall extending to the dome, muscle-invasive with extravesical extension (clinical stage cT3b N0 M0, stage IIIA), pure squamous histology without a urothelial component; treated with palliative-intent hypofractionated radiotherapy by shared decisionactiveconfirmed C67.4S — Synthetic modern diagnosis confirmed by resection pathology. His bladder disease at autopsy is documented (D); calling it squamous cell carcinoma is a 2025 retrospective interpretation (R, disputed).
Chronic constipation, lifelong by his account, with long use of laxatives and self-given enemasactiveconfirmed K59.09S — Synthetic modern problem echoing his documented colic, purges, and enemas; no diagnosis of inflammatory bowel disease is made.
Febrile catheter-associated urinary tract infection with Escherichia coli, five days after bladder tumor resection; treated with cefpodoxime and a catheter change; resolvedresolvedconfirmed T83.511AS — Synthetic intercurrent infection; it echoes, without asserting, the infected urine described in his last weeks (CLM-0009).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count and kidney function during radiotherapyAt each visit during treatmentCompleted todayHemoglobin 10.8 g/dL, white count 6.9, platelets 231; creatinine 1.20 mg/dL (eGFR 60), potassium 4.4 mmol/L; stable
ExaminationPost-void residualAt baseline when retention is suspected, after a trial without catheter, and when symptoms changeCompleted today120 mL, stable
SurveyIPSSBaseline and at every follow-up visit (CMID BPH)Completed today15, moderate; frequency from radiotherapy
SurveyPain intensity (0 to 10)At every visit with cancer painCompleted today2 of 10
ExaminationRadiation toxicity (bladder and bowel)Weekly during radiotherapyCompleted todayGrade 1 cystitis; no bowel toxicity or skin reaction
Medication safetyOpioid follow-up: benefit, sedation, falls, constipation, use against the plan, prescription monitoring program, and naloxone at homeWithin 1 to 4 weeks of starting, then at least every three monthsCompleted todayEight half tablets in fourteen days, as prescribed; no sedation or falls; bowels regular; prescription monitoring program shows only this prescription; naloxone at home and his assistant trained
ReferralHome physical therapy for strength and balanceWithin one to two weeks of the falls assessmentDeferredMissed: home physical therapy ordered at the wellness visit has not started because the agency had no therapist free. No harm: he has had no falls. Corrective action: the clinic arranged a second agency, which will visit this week, and gave him a printed set of chair exercises in the meantime
Self-managementWeight and nutritionAt every visit while weight is fallingCompleted today53.0 kg, down 0.5 kg; supplement once a day; asked to take it twice
ImagingBladder cancer surveillance schedule (cystoscopy and cytology for NMIBC; CT every 6 to 12 months after cystectomy)Applies after NMIBC treatment or cystectomyNot indicatedNeither applies: he has muscle-invasive disease treated with palliative-intent radiotherapy, so response is judged by symptoms, with cystoscopy or CT only if they would change care

Goal progress:

Guideline basis: Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026); Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment (Hafeez S, et al.) (2017); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024)

Follow-up: Chronic-care review in two weeks, after the fourth fraction; call for clots, a weak stream or inability to pass urine, fever, or pain not controlled. [S]